Figure 3.

Tumor progression in mice treated with combination therapy using single-peptide vaccines or immune cell depletions. A, Tumor growth in mice treated with N-803, anti–PD-L1, NHS-IL12, and a neoepitope vaccine consisting of a single 9-mer neoepitope or a pool of four 9-mer neoepitopes. Mice were treated according to the schedule in Fig. 2A (n = 6–7). B, Timeline (left) and tumor growth (right) of depletion studies. Tumor-bearing mice were depleted of NK, CD4⁺ T cells, or CD8⁺ T cells starting 3 days prior to the first vaccine (early depletion) or NHS-IL12 administration (late depletion) (n = 7–10).